These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 36253800)
1. A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients. Liu Z; Yang H; Chen Z; Jing C Hereditas; 2022 Oct; 159(1):40. PubMed ID: 36253800 [TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma. Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J Front Immunol; 2021; 12():788431. PubMed ID: 34970268 [TBL] [Abstract][Full Text] [Related]
3. Identification of a chromatin regulator signature and potential candidate drugs for bladder cancer. Zhu K; Liu X; Deng W; Wang G; Fu B Hereditas; 2022 Feb; 159(1):13. PubMed ID: 35125116 [TBL] [Abstract][Full Text] [Related]
4. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis. Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189 [TBL] [Abstract][Full Text] [Related]
5. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma. Lai J; Xu T; Yang H BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291 [TBL] [Abstract][Full Text] [Related]
6. Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma. Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H Biomed Res Int; 2022; 2022():2056913. PubMed ID: 35937391 [TBL] [Abstract][Full Text] [Related]
7. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma. Ouyang D; Li R; Li Y; Zhu X J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849 [TBL] [Abstract][Full Text] [Related]
8. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma. Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731 [TBL] [Abstract][Full Text] [Related]
9. Lactate metabolism-related genes to predict the clinical outcome and molecular characteristics of endometrial cancer. Shi R; Li H; Wei S; Yu Z; Zhang J; Zhang Q; Zhou T; Yao Y; Zhang Q; Zhang T; Wang H BMC Cancer; 2023 May; 23(1):491. PubMed ID: 37259038 [TBL] [Abstract][Full Text] [Related]
10. m Fang F; Wang P; Huang H; Ye M; Liu X; Li Q BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816 [TBL] [Abstract][Full Text] [Related]
11. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma. Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290 [TBL] [Abstract][Full Text] [Related]
12. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma. Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L Front Oncol; 2022; 12():1030246. PubMed ID: 36439473 [TBL] [Abstract][Full Text] [Related]
13. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients. Sun XX; Wen HQ; Zhan BX; Yang P Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230 [TBL] [Abstract][Full Text] [Related]
14. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma. Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000 [No Abstract] [Full Text] [Related]
15. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer. Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523 [TBL] [Abstract][Full Text] [Related]
16. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database. Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565 [TBL] [Abstract][Full Text] [Related]
17. Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma. Wang Y; Ren F; Song Z; Wang X; Ma X J Cancer; 2020; 11(21):6390-6401. PubMed ID: 33033522 [TBL] [Abstract][Full Text] [Related]
18. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer. Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615 [TBL] [Abstract][Full Text] [Related]
19. Development and validation of a novel DNA damage repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in uterine corpus endometrial carcinoma. Wang T; Ji M; Liu W; Sun J Comput Struct Biotechnol J; 2023; 21():4944-4959. PubMed ID: 37876625 [TBL] [Abstract][Full Text] [Related]
20. RNA modification regulator DDC in endometrial cancer affects the tumor microenvironment and patient prognosis. Zhao H; Shi C; Zhao G; Liu J; Wang X; Liang J; Li F Sci Rep; 2023 Oct; 13(1):18057. PubMed ID: 37872211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]